Stem definition | Drug id | CAS RN |
---|---|---|
retinol derivatives | 2722 | 302-79-4 |
None
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 3.70 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 20, 1971 | FDA | VALEANT INTL |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Differentiation syndrome | 600.18 | 16.69 | 104 | 6423 | 829 | 50597768 |
Idiopathic intracranial hypertension | 117.50 | 16.69 | 32 | 6495 | 2317 | 50596280 |
Blepharospasm | 110.30 | 16.69 | 32 | 6495 | 2916 | 50595681 |
Product use in unapproved indication | 109.47 | 16.69 | 102 | 6425 | 115717 | 50482880 |
Intracranial pressure increased | 86.68 | 16.69 | 29 | 6498 | 4223 | 50594374 |
Leukaemia recurrent | 76.54 | 16.69 | 20 | 6507 | 1234 | 50597363 |
Taste disorder | 74.39 | 16.69 | 31 | 6496 | 8293 | 50590304 |
Epilepsy | 49.01 | 16.69 | 32 | 6495 | 21535 | 50577062 |
Haematopoietic neoplasm | 42.99 | 16.69 | 7 | 6520 | 36 | 50598561 |
Polyarteritis nodosa | 35.68 | 16.69 | 8 | 6519 | 257 | 50598340 |
Lower respiratory tract infection fungal | 34.83 | 16.69 | 8 | 6519 | 287 | 50598310 |
Migraine | 33.82 | 16.69 | 45 | 6482 | 75235 | 50523362 |
Dysphoria | 33.53 | 16.69 | 15 | 6512 | 4759 | 50593838 |
Dry skin | 33.13 | 16.69 | 34 | 6493 | 43157 | 50555440 |
Hypoaesthesia | 33.04 | 16.69 | 59 | 6468 | 127198 | 50471399 |
Haemorrhagic diathesis | 32.92 | 16.69 | 14 | 6513 | 3934 | 50594663 |
Skin warm | 30.48 | 16.69 | 14 | 6513 | 4721 | 50593876 |
Chromosomal deletion | 29.65 | 16.69 | 5 | 6522 | 33 | 50598564 |
Disseminated intravascular coagulation | 28.52 | 16.69 | 21 | 6506 | 17114 | 50581483 |
Myelodysplastic syndrome | 28.52 | 16.69 | 20 | 6507 | 15112 | 50583485 |
Gastrooesophageal reflux disease | 27.37 | 16.69 | 41 | 6486 | 76387 | 50522210 |
Appetite disorder | 27.07 | 16.69 | 14 | 6513 | 6100 | 50592497 |
Chloroma | 26.41 | 16.69 | 6 | 6521 | 205 | 50598392 |
Arthritis infective | 25.38 | 16.69 | 13 | 6514 | 5556 | 50593041 |
Neutropenic sepsis | 25.05 | 16.69 | 18 | 6509 | 14129 | 50584468 |
Xerosis | 24.20 | 16.69 | 7 | 6520 | 630 | 50597967 |
Acute myeloid leukaemia | 24.02 | 16.69 | 18 | 6509 | 15056 | 50583541 |
Myocarditis | 23.64 | 16.69 | 14 | 6513 | 7933 | 50590664 |
Memory impairment | 23.47 | 16.69 | 39 | 6488 | 79321 | 50519276 |
Febrile neutropenia | 22.46 | 16.69 | 43 | 6484 | 97624 | 50500973 |
Oesophageal mass | 21.28 | 16.69 | 4 | 6523 | 52 | 50598545 |
Thinking abnormal | 21.25 | 16.69 | 14 | 6513 | 9553 | 50589044 |
Tenderness | 20.72 | 16.69 | 18 | 6509 | 18547 | 50580050 |
Gambling | 20.54 | 16.69 | 5 | 6522 | 231 | 50598366 |
Paraesthesia | 19.59 | 16.69 | 46 | 6481 | 120197 | 50478400 |
Neutropenia | 19.29 | 16.69 | 52 | 6475 | 147913 | 50450684 |
Sweat gland tumour | 18.66 | 16.69 | 4 | 6523 | 104 | 50598493 |
VIth nerve paralysis | 18.54 | 16.69 | 6 | 6521 | 787 | 50597810 |
Lip dry | 18.47 | 16.69 | 10 | 6517 | 4777 | 50593820 |
Papilloedema | 18.46 | 16.69 | 9 | 6518 | 3464 | 50595133 |
Photophobia | 17.77 | 16.69 | 15 | 6512 | 14872 | 50583725 |
Erythema | 17.64 | 16.69 | 50 | 6477 | 146364 | 50452233 |
Hypercalcaemia | 17.21 | 16.69 | 18 | 6509 | 23334 | 50575263 |
Chloasma | 16.87 | 16.69 | 3 | 6524 | 28 | 50598569 |
Application site dryness | 16.85 | 16.69 | 4 | 6523 | 166 | 50598431 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Differentiation syndrome | 751.97 | 26.39 | 121 | 2307 | 992 | 29571107 |
Idiopathic intracranial hypertension | 195.41 | 26.39 | 35 | 2393 | 560 | 29571539 |
Product use in unapproved indication | 84.24 | 26.39 | 64 | 2364 | 86811 | 29485288 |
Haematopoietic neoplasm | 82.44 | 26.39 | 12 | 2416 | 44 | 29572055 |
Acute myeloid leukaemia | 80.38 | 26.39 | 35 | 2393 | 16478 | 29555621 |
Hyperleukocytosis | 80.29 | 26.39 | 20 | 2408 | 1615 | 29570484 |
Leukaemia recurrent | 72.19 | 26.39 | 18 | 2410 | 1459 | 29570640 |
Electrocardiogram QT prolonged | 69.94 | 26.39 | 41 | 2387 | 36096 | 29536003 |
Cytogenetic abnormality | 55.54 | 26.39 | 13 | 2415 | 806 | 29571293 |
Scrotal ulcer | 48.26 | 26.39 | 10 | 2418 | 351 | 29571748 |
Hypokalaemia | 44.19 | 26.39 | 35 | 2393 | 50168 | 29521931 |
Febrile neutropenia | 39.09 | 26.39 | 47 | 2381 | 112193 | 29459906 |
Myelodysplastic syndrome | 36.52 | 26.39 | 21 | 2407 | 17773 | 29554326 |
IIIrd nerve paralysis | 35.02 | 26.39 | 8 | 2420 | 445 | 29571654 |
Neutropenia | 34.64 | 26.39 | 48 | 2380 | 131663 | 29440436 |
Hypomagnesaemia | 31.59 | 26.39 | 19 | 2409 | 17449 | 29554650 |
Lymphopenia | 30.54 | 26.39 | 17 | 2411 | 13516 | 29558583 |
Large granular lymphocytosis | 29.49 | 26.39 | 6 | 2422 | 192 | 29571907 |
Activated partial thromboplastin time prolonged | 26.90 | 26.39 | 13 | 2415 | 7729 | 29564370 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Differentiation syndrome | 1284.49 | 17.59 | 221 | 7534 | 1833 | 64489144 |
Idiopathic intracranial hypertension | 240.41 | 17.59 | 57 | 7698 | 2536 | 64488441 |
Myelodysplastic syndrome transformation | 160.18 | 17.59 | 32 | 7723 | 627 | 64490350 |
Product use in unapproved indication | 129.38 | 17.59 | 131 | 7624 | 176487 | 64314490 |
Leukaemia recurrent | 107.36 | 17.59 | 30 | 7725 | 2564 | 64488413 |
Blepharospasm | 99.56 | 17.59 | 30 | 7725 | 3345 | 64487632 |
Hyperleukocytosis | 90.89 | 17.59 | 25 | 7730 | 2015 | 64488962 |
Acute myeloid leukaemia | 81.24 | 17.59 | 47 | 7708 | 27416 | 64463561 |
Haematopoietic neoplasm | 71.63 | 17.59 | 12 | 7743 | 82 | 64490895 |
Intracranial pressure increased | 67.57 | 17.59 | 27 | 7728 | 6962 | 64484015 |
Cytogenetic abnormality | 66.43 | 17.59 | 17 | 7738 | 1037 | 64489940 |
Taste disorder | 66.19 | 17.59 | 29 | 7726 | 9404 | 64481573 |
Myelodysplastic syndrome | 58.07 | 17.59 | 38 | 7717 | 27541 | 64463436 |
Electrocardiogram QT prolonged | 49.22 | 17.59 | 54 | 7701 | 79394 | 64411583 |
Second primary malignancy | 47.13 | 17.59 | 25 | 7730 | 12312 | 64478665 |
Febrile neutropenia | 46.61 | 17.59 | 82 | 7673 | 187575 | 64303402 |
Hypercalcaemia | 42.36 | 17.59 | 33 | 7722 | 31383 | 64459594 |
Myocarditis | 37.14 | 17.59 | 24 | 7731 | 17019 | 64473958 |
Neutropenia | 35.98 | 17.59 | 85 | 7670 | 239539 | 64251438 |
Disseminated intravascular coagulation | 35.22 | 17.59 | 30 | 7725 | 32318 | 64458659 |
Migraine | 34.37 | 17.59 | 40 | 7715 | 62637 | 64428340 |
Dysphoria | 32.44 | 17.59 | 14 | 7741 | 4374 | 64486603 |
Epilepsy | 32.29 | 17.59 | 29 | 7726 | 33502 | 64457475 |
Polyarteritis nodosa | 31.63 | 17.59 | 8 | 7747 | 465 | 64490512 |
Gastrointestinal toxicity | 29.85 | 17.59 | 14 | 7741 | 5308 | 64485669 |
Hypoaesthesia | 28.50 | 17.59 | 56 | 7699 | 139052 | 64351925 |
Chloroma | 28.47 | 17.59 | 8 | 7747 | 697 | 64490280 |
Lower respiratory tract infection fungal | 26.94 | 17.59 | 8 | 7747 | 847 | 64490130 |
Haemorrhagic diathesis | 26.36 | 17.59 | 13 | 7742 | 5501 | 64485476 |
Chromosomal deletion | 25.53 | 17.59 | 5 | 7750 | 88 | 64490889 |
IIIrd nerve paralysis | 25.14 | 17.59 | 8 | 7747 | 1066 | 64489911 |
White blood cell count increased | 24.92 | 17.59 | 35 | 7720 | 65979 | 64424998 |
Scrotal ulcer | 24.55 | 17.59 | 6 | 7749 | 303 | 64490674 |
Appetite disorder | 24.41 | 17.59 | 13 | 7742 | 6448 | 64484529 |
Large granular lymphocytosis | 23.82 | 17.59 | 6 | 7749 | 343 | 64490634 |
Papilloedema | 23.44 | 17.59 | 12 | 7743 | 5493 | 64485484 |
Acute promyelocytic leukaemia | 23.13 | 17.59 | 8 | 7747 | 1380 | 64489597 |
Skin warm | 23.01 | 17.59 | 12 | 7743 | 5705 | 64485272 |
Dry skin | 22.15 | 17.59 | 29 | 7726 | 51132 | 64439845 |
Ciliary body melanoma | 22 | 17.59 | 3 | 7752 | 3 | 64490974 |
Bone marrow necrosis | 21.69 | 17.59 | 5 | 7750 | 196 | 64490781 |
Gastrooesophageal reflux disease | 21.46 | 17.59 | 37 | 7718 | 83106 | 64407871 |
Tenderness | 20.97 | 17.59 | 18 | 7737 | 19584 | 64471393 |
Acute myeloid leukaemia recurrent | 20.96 | 17.59 | 9 | 7746 | 2775 | 64488202 |
Photophobia | 20.81 | 17.59 | 17 | 7738 | 17276 | 64473701 |
Arthritis infective | 20.69 | 17.59 | 12 | 7743 | 7018 | 64483959 |
Oesophageal mass | 20.61 | 17.59 | 4 | 7751 | 67 | 64490910 |
Thinking abnormal | 19.74 | 17.59 | 14 | 7741 | 11542 | 64479435 |
Acute febrile neutrophilic dermatosis | 19.42 | 17.59 | 9 | 7746 | 3320 | 64487657 |
Memory impairment | 19.39 | 17.59 | 36 | 7719 | 85646 | 64405331 |
Hypomagnesaemia | 19.07 | 17.59 | 23 | 7732 | 37353 | 64453624 |
Paraesthesia | 18.31 | 17.59 | 46 | 7709 | 134476 | 64356501 |
Pulmonary tuberculosis | 17.77 | 17.59 | 11 | 7744 | 7233 | 64483744 |
Gelatinous transformation of the bone marrow | 17.60 | 17.59 | 3 | 7752 | 23 | 64490954 |
None
Source | Code | Description |
---|---|---|
ATC | D10AD01 | DERMATOLOGICALS ANTI-ACNE PREPARATIONS ANTI-ACNE PREPARATIONS FOR TOPICAL USE Retinoids for topical use in acne |
ATC | D10AD51 | DERMATOLOGICALS ANTI-ACNE PREPARATIONS ANTI-ACNE PREPARATIONS FOR TOPICAL USE Retinoids for topical use in acne |
ATC | L01XF01 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Retinoids for cancer treatment |
FDA CS | M0018962 | Retinoids |
CHEBI has role | CHEBI:22586 | antioxidants |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
CHEBI has role | CHEBI:50176 | keratolytic drugs |
CHEBI has role | CHEBI:62488 | signal molecules |
CHEBI has role | CHEBI:63794 | retinoid X receptor agonists |
CHEBI has role | CHEBI:67079 | anti-inflammatory agents |
CHEBI has role | CHEBI:67198 | retinoic acid receptor agonists |
CHEBI has role | CHEBI:67199 | activator protein-1 antagonists |
CHEBI has role | CHEBI:77746 | Homo sapiens metabolite |
FDA EPC | N0000175607 | Retinoid |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D003879 | Dermatologic Agents |
MeSH PA | D007641 | Keratolytic Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Chloasma | indication | 36209000 | |
Acne vulgaris | indication | 88616000 | |
Acute promyelocytic leukemia, FAB M3 | indication | 110004001 | |
Hyperkeratosis | indication | 396228006 | |
Facial Fine Wrinkling | indication | ||
Solar Lentigines | indication | ||
Fine Wrinkling | indication | ||
Severe Recalcitrant Nodular Acne | indication | ||
Kaposi's Sarcoma Skin Lesions | indication | ||
Mottle Hyperpigmentation | indication | ||
Keratosis follicularis | off-label use | 48611009 | DOID:2734 |
Lamellar ichthyosis | off-label use | 205550003 | |
Plane wart | off-label use | 240539000 | |
Primary cutaneous T-cell lymphoma | off-label use | 400122007 | |
Severe Recalcitrant Nodular Rosacea | off-label use | ||
Osteomalacia | contraindication | 4598005 | DOID:10573 |
Suicidal thoughts | contraindication | 6471006 | |
Alcoholism | contraindication | 7200002 | |
Rectal hemorrhage | contraindication | 12063002 | |
Hypercholesterolemia | contraindication | 13644009 | |
Hearing loss | contraindication | 15188001 | |
Agranulocytosis | contraindication | 17182001 | DOID:12987 |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Sunburn | contraindication | 23346002 | |
Atopic dermatitis | contraindication | 24079001 | DOID:3310 |
Inflammatory bowel disease | contraindication | 24526004 | DOID:0050589 |
Crohn's disease | contraindication | 34000006 | |
Depressive disorder | contraindication | 35489007 | |
Eczema | contraindication | 43116000 | |
Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
Vitiligo | contraindication | 56727007 | DOID:12306 |
Anorexia nervosa | contraindication | 56882008 | DOID:8689 |
Tinnitus | contraindication | 60862001 | |
Corneal opacity | contraindication | 64634000 | |
Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
Osteoporosis | contraindication | 64859006 | DOID:11476 |
Benign intracranial hypertension | contraindication | 68267002 | DOID:11459 |
Psychotic disorder | contraindication | 69322001 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Disorder of bone | contraindication | 76069003 | DOID:0080001 |
Congenital neutropenia | contraindication | 89655007 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Venous thrombosis | contraindication | 111293003 | |
Leukocytosis | contraindication | 111583006 | |
Mycosis fungoides | contraindication | 118618005 | |
Inflammatory disease of liver | contraindication | 128241005 | |
Bleeding | contraindication | 131148009 | |
Liver function tests abnormal | contraindication | 166603001 | |
Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Telangiectasia disorder | contraindication | 247479008 | |
Dyspnea | contraindication | 267036007 | |
Edema | contraindication | 267038008 | |
Pregnancy, function | contraindication | 289908002 | |
Hypertriglyceridemia | contraindication | 302870006 | |
Keratoconjunctivitis sicca | contraindication | 302896008 | DOID:12895 |
Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
Pericardial effusion | contraindication | 373945007 | DOID:118 |
Adrenal cortical hypofunction | contraindication | 386584007 | DOID:10493 |
Fever | contraindication | 386661006 | |
Pseudomembranous enterocolitis | contraindication | 397683000 | |
Atrophoderma | contraindication | 399979006 | |
Peripheral vascular disease | contraindication | 400047006 | |
Severe diarrhea | contraindication | 409587002 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Obesity | contraindication | 414916001 | DOID:9970 |
Denuded skin | contraindication | 418242004 | |
Retinoic acid syndrome | contraindication | 450887006 | |
Pulmonary Infiltrates | contraindication | ||
Pleural Effusions | contraindication | ||
Predisposition To Hypertriglyceridemia | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 4.17 | acidic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
3%;0.1% | TWYNEO | GALDERMA LABS LP | N214902 | July 26, 2021 | RX | CREAM | TOPICAL | 9868103 | Aug. 8, 2028 | TOPICAL TREATMENT OF ACNE VULGARIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER |
3%;0.1% | TWYNEO | GALDERMA LABS LP | N214902 | July 26, 2021 | RX | CREAM | TOPICAL | 10653899 | Dec. 30, 2030 | TOPICAL TREATMENT OF ACNE VULGARIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER |
3%;0.1% | TWYNEO | GALDERMA LABS LP | N214902 | July 26, 2021 | RX | CREAM | TOPICAL | 10420743 | July 12, 2038 | TOPICAL TREATMENT OF ACNE VULGARIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER |
0.05% | ALTRENO | DOW PHARM | N209353 | Aug. 23, 2018 | RX | LOTION | TOPICAL | 10653656 | Aug. 22, 2038 | TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 9 YEARS OF AGE AND OLDER |
0.05% | ALTRENO | DOW PHARM | N209353 | Aug. 23, 2018 | RX | LOTION | TOPICAL | 11324710 | Aug. 22, 2038 | TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 9 YEARS OF AGE AND OLDER |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
1.2%;0.025% | CLINDAMYCIN PHOSPHATE AND TRETINOIN | SOLARIS PHARMA CORP | A212845 | Feb. 10, 2022 | RX | GEL | TOPICAL | Oct. 9, 2022 | COMPETITIVE GENERIC THERAPY |
3%;0.1% | TWYNEO | GALDERMA LABS LP | N214902 | July 26, 2021 | RX | CREAM | TOPICAL | July 26, 2024 | NEW COMBINATION |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Retinoic acid receptor beta | Nuclear hormone receptor | AGONIST | EC50 | 6.70 | WOMBAT-PK | CHEMBL | |||
Retinoic acid receptor gamma | Nuclear hormone receptor | AGONIST | EC50 | 6.70 | WOMBAT-PK | CHEMBL | |||
Retinoic acid receptor alpha | Nuclear hormone receptor | AGONIST | EC50 | 6.70 | WOMBAT-PK | CHEMBL | |||
Nuclear receptor ROR-alpha | Nuclear hormone receptor | IC50 | 6.70 | CHEMBL | |||||
Retinoic acid receptor RXR-alpha | Nuclear hormone receptor | Ki | 9.40 | CHEMBL | |||||
Retinoic acid receptor RXR-beta | Nuclear hormone receptor | Ki | 9.30 | CHEMBL | |||||
Retinoic acid receptor RXR-gamma | Nuclear hormone receptor | Ki | 8.85 | CHEMBL | |||||
Peroxisome proliferator-activated receptor delta | Nuclear hormone receptor | AGONIST | Kd | 7.80 | IUPHAR | ||||
Nuclear receptor ROR-beta | Nuclear hormone receptor | ANTAGONIST | IC50 | 9.82 | IUPHAR | ||||
Nuclear receptor ROR-gamma | Nuclear hormone receptor | IC50 | 6.70 | CHEMBL | |||||
Mitogen-activated protein kinase 1 | Kinase | IC50 | 6.24 | DRUG MATRIX | |||||
Nuclear receptor subfamily 2 group E member 1 | Nuclear hormone receptor | AGONIST | EC50 | 5.74 | IUPHAR | ||||
Amyloid beta A4 protein | Unclassified | IC50 | 6.75 | CHEMBL | |||||
Nuclear receptor subfamily 2 group C member 2 | Nuclear other | AGONIST | EC50 | 4.62 | IUPHAR | ||||
Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Unclassified | IC50 | 6.09 | CHEMBL | |||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 6.64 | DRUG MATRIX | |||||
Alpha-synuclein | Transporter | IC50 | 5.52 | CHEMBL | |||||
Adenosine receptor A3 | GPCR | Ki | 5.53 | DRUG MATRIX | |||||
11-cis retinol dehydrogenase | Enzyme | Ki | 7 | WOMBAT-PK | |||||
Cellular retinoic acid-binding protein 1 | Cytosolic other | IC50 | 6.43 | CHEMBL | |||||
Retinoic acid receptor RXR-beta | Transcription factor | Kd | 6.51 | CHEMBL | |||||
Retinoic acid receptor RXR-gamma | Transcription factor | Kd | 6.46 | CHEMBL | |||||
Cellular retinoic acid-binding protein 1 | Cytosolic other | Kd | 9.40 | CHEMBL | |||||
Cellular retinoic acid-binding protein 2 | Cytosolic other | Kd | 8.70 | CHEMBL | |||||
Retinoic acid receptor alpha | Transcription factor | Kd | 7.82 | CHEMBL | |||||
Retinoic acid receptor RXR-alpha | Transcription factor | Kd | 6 | CHEMBL | |||||
Retinoic acid receptor beta | Transcription factor | Kd | 7.89 | CHEMBL | |||||
Retinoic acid receptor gamma | Transcription factor | Kd | 7.74 | CHEMBL | |||||
Indoleamine 2,3-dioxygenase 2 | Enzyme | IC50 | 4.54 | CHEMBL |
ID | Source |
---|---|
4018550 | VUID |
N0000146871 | NUI |
D00094 | KEGG_DRUG |
4018550 | VANDF |
C0040845 | UMLSCUI |
CHEBI:15367 | CHEBI |
3KV | PDB_CHEM_ID |
CHEMBL38 | ChEMBL_ID |
DB00755 | DRUGBANK_ID |
D014212 | MESH_DESCRIPTOR_UI |
444795 | PUBCHEM_CID |
2644 | IUPHAR_LIGAND_ID |
2875 | INN_ID |
5688UTC01R | UNII |
10753 | RXNORM |
46802 | MMSL |
5610 | MMSL |
d03863 | MMSL |
001954 | NDDF |
387305002 | SNOMEDCT_US |
54972005 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Altreno | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-0005 | LOTION | 0.50 mg | TOPICAL | NDA | 24 sections |
Retin-A MICRO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-5140 | GEL | 1 mg | TOPICAL | NDA | 26 sections |
Retin-A MICRO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-5140 | GEL | 1 mg | TOPICAL | NDA | 26 sections |
Retin-A MICRO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-5144 | GEL | 0.40 mg | TOPICAL | NDA | 26 sections |
Retin-A MICRO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-5144 | GEL | 0.40 mg | TOPICAL | NDA | 26 sections |
Retin-A MICRO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-5146 | GEL | 0.60 mg | TOPICAL | NDA | 26 sections |
Retin-A MICRO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-5146 | GEL | 0.60 mg | TOPICAL | NDA | 26 sections |
Retin-A MICRO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-5148 | GEL | 0.80 mg | TOPICAL | NDA | 26 sections |
Retin-A MICRO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-5148 | GEL | 0.80 mg | TOPICAL | NDA | 26 sections |
Renova | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-5150 | CREAM | 0.20 mg | TOPICAL | NDA | 25 sections |
Retin-A | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-5160 | CREAM | 0.25 mg | TOPICAL | NDA | 21 sections |
Retin-A | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-5162 | CREAM | 0.50 mg | TOPICAL | NDA | 21 sections |
Retin-A | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-5164 | CREAM | 1 mg | TOPICAL | NDA | 21 sections |
Retin-A | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-5170 | GEL | 0.25 mg | TOPICAL | NDA | 21 sections |
Retin-A | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-5172 | GEL | 0.10 mg | TOPICAL | NDA | 21 sections |
TWYNEO | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0299-5945 | CREAM | 1 mg | TOPICAL | NDA | 26 sections |
TRI-LUMA | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0299-5950 | CREAM | 0.50 mg | TOPICAL | NDA | 24 sections |
TRI-LUMA | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0299-5950 | CREAM | 0.50 mg | TOPICAL | NDA | 24 sections |
Avita | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-6140 | GEL | 0.25 mg | TOPICAL | NDA | 22 sections |
Avita | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-6141 | CREAM | 0.25 mg | TOPICAL | NDA | 21 sections |
Tretinoin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-8082 | CREAM | 0.25 mg | TOPICAL | NDA authorized generic | 20 sections |
Tretinoin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-8083 | CREAM | 0.50 mg | TOPICAL | NDA authorized generic | 20 sections |
Tretinoin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-8084 | CREAM | 1 mg | TOPICAL | NDA authorized generic | 20 sections |
Tretinoin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-8085 | GEL | 0.10 mg | TOPICAL | NDA authorized generic | 20 sections |
Tretinoin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-8086 | GEL | 0.25 mg | TOPICAL | NDA authorized generic | 20 sections |
Tretinoin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-8090 | GEL | 0.50 mg | TOPICAL | ANDA | 24 sections |
Tretinoin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-8092 | GEL | 0.40 mg | TOPICAL | NDA authorized generic | 25 sections |
Tretinoin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-8093 | GEL | 1 mg | TOPICAL | NDA authorized generic | 25 sections |
Tretinoin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0472-0117 | CREAM | 0.25 mg | TOPICAL | NDA AUTHORIZED GENERIC | 22 sections |
Clindamycin Phosphate and Tretinoin | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0472-1790 | GEL | 0.25 mg | TOPICAL | ANDA | 16 sections |